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Anti-parasitic treatment for Chagas disease mainly relies on benznidazole, which
is virtually the only drug available in the market. Besides its anti-parasitic effects,
benznidazole has anti-inflammatory properties. In this work we studied the mechanisms
involved in the latter, demonstrating the participation of the IL-10/STAT3/SOCS3
pathway. To achieve this goal, the anti-inflammatory properties of benznidazole were
studied using an in vitro model of cardiomyocyte primary culture stimulated with LPS.
LPS increased both SOCS3 expression and STAT3 phosphorylation. The addition
of benznidazole increased their expression even further. Specific inhibition of STAT3
precluded this effect, suggesting a role for STAT3 in the increase of SOCS3 expression
induced by benznidazole. To assess the participation of SOCS3 in the anti-inflammatory
effect of benznidazole, we accomplished specific knockdown of SOCS3 with siRNA.
Silencing of SOCS3 in cardiomyocytes precluded the inhibitory effects of benznidazole
on TNF-α, IL-6, iNOS expression and NO release. Moreover, in the absence of
SOCS3, benznidazole could neither prevent IKK phosphorylation nor IκBα degradation,
supporting the notion that SOCS3 is required for the benznidazole-mediated inhibition of
the NF-κB pathway. Previously, we demonstrated that IL-10 increases the expression of
SOCS3 in cultured cardiomyocytes. Here, we found that benznidazole shows a trend to
increased IL-10 expression. To evaluate whether benznidazole increased SOCS3 in an
IL-10-dependent manner, cardiomyocytes from IL-10 knockout mice were pre-treated
with benznidazole and stimulated with LPS. Benznidazole neither inhibited NO release
nor avoid IKK phosphorylation or IκBα degradation, showing that IL-10 is required for
benznidazole-mediated inhibition of NF-κB. Moreover, exogenous addition of IL-10 to IL-
10 knockout cardiomyocytes restored the inhibitory effect of benznidazole on NO release.
The results reported herein show, for the first time, that the IL-10/STAT3/SOCS3 axis is
involved in the anti-inflammatory effects of benznidazole. These findings may add up to
new therapeutic strategies for chronic Chagas disease given its inflammatory nature.
Keywords: benznidazole, anti-inflammatory effects, cardiomyocytes, mechanism of action, inflammatory
mediators
Cevey et al. Benznidazole Modulates Inflammation Through IL-10/STAT3/SOCS3
INTRODUCTION
American trypanosomiasis is an endemic parasitic disease caused
by infection with the obligate intracellular protozoan parasite
Trypanosoma cruzi (T. cruzi). It spans throughout Central and
South America and represents a major public health concern due
to its high morbidity and mortality rates (1). Benznidazole (N-
benzyl-2-(2-nitroimidazol-1-yl)acetamide) is one of the drugs
of choice for its treatment (2) despite its toxicity and limited
efficacy, particularly during the chronic phase of the disease.
Although benznidazole has long been used in clinical settings,
its mechanisms of action have not been fully elucidated yet.
Indeed, there is a general premise that the etiological treatment
contributes to a reduction of the parasite load and to fit the host
immune response, leading to a balanced inflammatory response
which is crucial to control Chagas disease morbidity (3, 4). In a
previous work, Campi-Azevedo et al. highlighted that treatment
with benznidazole in the indeterminate phase of the disease not
only leads to parasite clearance but also would contribute to a
general immunomodulation. Induction of a broad change in the
immune response was observed in patients in the cardiac phase,
shaping an intricate phenotypic/functional network compatible
with beneficial and protective immunological events (5). In
this regard, we have recently shown in an experimental
murine model of acute Chagas disease, using a highly virulent
benznidazole-susceptible T. cruzi strain, that the optimal effects
of benznidazole, in terms of parasite clearance from blood and
heart tissue, as well as the reduction of inflammatory reaction,
can be achieved at doses significantly lower than those usually
used for the treatment (6).
In addition to its antiparasitic activity, benznidazole exerts
immunomodulatory effects on macrophages stimulated with
lipopolysaccharide (LPS) and treated with a high concentration
of benznidazole (1mM), by inhibiting the NF-κB pathway
(7). These in vitro effects have also been described in LPS-
challenged mice pre-treated with high doses of benznidazole
(200 mg/Kg/day) (8). Like LPS, certain T. cruzi components,
such as glycoinositolphospholipids, are recognized by TLR4 and
induce pro-inflammatory cytokines. Thus, in order to distinguish
the anti-inflammatory effects from the anti-parasitic effects of
benznidazole, we used LPS in experimental settings aimed at
exploring its anti-inflammatory mechanism of action (9, 10).
Interestingly, anti-inflammatory as well as anti-parasitic effects
were achieved using 15µM of benznidazole, a concentration
rendering parasite DNA almost undetectable by qPCR (6).
Interleukin-10 (IL-10), a well-known anti-inflammatory
cytokine, is produced by a range of cells such as T cells, B cells,
macrophages, and dendritic cells. Its expression is regulated by
multiple signaling molecules, including p38 MAPK and ERK1/2
(11). One of the main biological function of IL-10 is to counter
the production of inflammatory mediators, especially in response
to TLR signaling (12–16). The binding of IL-10 to the IL-
10R results in the activation of JAK1 which induces STAT3
phosphorylation. It has been demonstrated that STAT3 is a key
effector molecule of IL-10 action. Its activation is necessary for
the IL-10-regulated anti-inflammatory effects (17–20). Although
better studied in macrophages (17, 21–26), the IL-10/STAT3
anti-inflammatory pathway has long been known to extend to
other cells of the immune system (19, 27–30), and non-immune
cells (31–35).
Both IL-10 and Interleukin-6 (IL-6) induce the activation
of STAT3, yet generate different cellular responses. While IL-
6 stimulation promotes a pro-inflammatory response, IL-10
signaling induces a strong anti-inflammatory one (36). Activated
STATs not only drive transcription of many genes related to
cell proliferation, function, and survival, but also induce the
transcription of SOCS genes (37). SOCS3, one of the better
studied members of the SOCS family, controls critical cellular
processes such as cell growth, apoptosis, and transcription of
inflammatory genes (38). It also regulates the kinetics of STAT3
activation, determining the pattern of responsive genes in the
case of IL-6 and IL-10 (36).
Induction of SOCS3 by STAT3 results in a negative feedback
loop, via binding to the gp130 subunit of the IL-6 receptor,
which results in transient STAT3 activation with a rapid
decline in phosphorylation and nuclear localization. In contrast,
SOCS3 does not block IL-10 activation of STAT3, thereby
inducing sustained STAT3 activation (39, 40). This confers
a particular timing to the initiation and perpetuation of the
inflammatory response.
We have described that 15µM of benznidazole has the
ability to inhibit the NF-κB pathway, demonstrating that the
anti-inflammatory effects of this drug may be attained at a
concentration lower than that reported elsewhere (6).
The aim of this work is to deepen into the mechanisms
involved in the anti-inflammatory effects of benznidazole, as
they have not yet been fully elucidated. Our results show that
benznidazole leads to STAT3 activation and up-regulation of
SOCS3. Moreover, we demonstrate for the first time that IL-10




To carry out this work, CF1, BALB/c, and BALB/c-background
IL-10 knockout mice, homozygous for the targeted mutation
Il10tm1Cgn (Stock Number 004333; The Jackson Laboratory,
USA) (41) were used. All the animals were bred and maintained
in the animal facility at the Instituto de Investigaciones en
Microbiología y Parasitología Médica, Universidad de Buenos
Aires—CONICET. All the procedures were approved by the
Institutional Committee for the Care and Use of Laboratory
Animals (CICUAL, Facultad de Medicina de la Universidad de
Buenos Aires, CD N◦ 2271/2014), in line with guidelines of
the Argentinean National Administration of Medicines, Food,
andMedical Devices (ANMAT), Argentinean National Service of
Agri-Food Health and Quality (SENASA) and with the Guide for
the Care and Use of Laboratory Animals (NIH, USA).
In vitro Model: Neonatal Mouse Primary
Cardiomyocytes Culture and Stimulation
For each experiment, 20–30 neonatal mice (One- to three-
day old, male, and female, 2–3 g weight) were euthanized
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by decapitation after CO2 exposure, and cardiomyocytes
were obtained as described previously (6). Briefly, the hearts
were removed aseptically, pooled and maintained in Hank’s
Buffer Saline Solution (HBSS). The hearts were mechanically
disaggregated, and the cells were isolated after several digestions
with porcine pancreas trypsin (0.25% w/v in PBS). The cells
were plated in culture plates in order to generate five replicates
per experimental group, with complete medium (10% FBS-
DMEM-M199-PenStrep R©) at 37◦C in a 5% CO2 atmosphere,
up to 80% confluence. Then, the cells were maintained with
1% FBS-DMEM-M199 -PenStrep R©, at least for a day before the
experiments were performed. For SOCS3 silencing experiments
using SOCS3 siRNA and oligofectamine R©, cells were cultured up
to 30% confluence with complete medium, and maintained with
DMEM-M199medium (without FBS and PenStrep R©), at least for
a day before stimulation.
In vitro Treatments
Benznidazole (Abarax R©, ELEA, Argentina. PubChem
Compound Database CID = 31,593, Figure 1A) was suspended
in PBS. According to the experiment, stimulated cells were pre-
treated with benznidazole 15µM for 30min before stimulation
with LPS in DMEM.
Recombinant Mouse Interleukin-10 (rm IL-10, Immunotools
Cat. #12340102) was suspended in PBS. Cardiomyocytes were
treated with 50 ng/mL of rmIL-10 for 30min before benznidazole
treatment and LPS stimulation.
In vitro Stimulation
The cardiomyocytes were stimulated with LPS (10µg/ml) from
Escherichia coli O26:B6 (Sigma-Aldrich Co, USA), for the
indicated period of time, in polystyrene culture plates. Each
independent experiment was carried out three times, with five
replicates per experimental group each one.
STAT3 Inhibition
Cardiomyocytes were treated with 10µM of the specific STAT3
Inhibitor V, Stattic (Santa Cruz Biotechnology, USA), 30min
before benznidazole treatment and LPS stimulation. Stattic
inhibits the activation of the STAT3 transcription factor by
blocking phosphorylation and dimerization events (31, 42).
Briefly, Static was re-suspended in DMSO to generate a 50mM
stock solution. Working solution (500µM) was generated
diluting the stock solution in PBS (Final concentration of DMSO:
1%). PBS/DMSO was added to each untreated well in order
to perform vehicle controls (Final concentration of DMSO, 1%
in PBS).
SOCS3 Knockdown With Small Interfering RNA
(siRNA)
Cardiomyocytes were cultured up to 30–50% of confluence in
DMEM: M-199 medium containing 5% FCS without antibiotics
for 24 h. Thereafter, cells were transfected with 20µM of
SOCS3-BLOCKiTTMsiRNA that targets SOCS3 mRNA (siRNA
duplex: 5′-GUAUGAUGCUCCACUUUAATT-3′, 5′-UUAAAG
UGGAGCAUCAUACTT-3′), following the manufacturer’s
instructions (Life Technologies Inc., USA). Transfections
were performed with Oligofectamine (Life Technologies,
Inc., USA) as specified by the manufacturer. Assays for gene
activity were performed at 72 h post-transfection. The impact
of SOCS3-siRNA interference on SOCS3 mRNA was evaluated
by RT-qPCR.
RNA Purification
Total RNA was obtained from cardiomyocytes using Quickzol
reagent (Kalium Technologies, Argentina), treated with RQ1
RNase-Free DNase (Promega Co., USA). Total RNA was reverse-
transcribed using M-MLV Reverse Transcriptase (Promega Co.,
USA), according to manufacturer’s instructions.
Quantitative Reverse Transcription
Polymerase Chain Reaction (RT-qPCR)
mRNA expression was determined using 5X HOT FIREPOL
EVAGREEN qPCR (Solis BioDyne, Estonia) in a StepOnePlus
Real-Time PCR System. Parameters were: 52◦C for 2min,
95◦C for 15min, and 40 cycles at 95◦C for 15 s, specific Tm
◦C for 30 s and 72◦C for 1min. Normalization was carried
out using 18S rRNA. Quantification was performed using the
comparative threshold cycle (Ct) method, as all the primer pairs
(target gene/reference gene) were amplified using comparable
efficiencies (relative quantity, 2−11Ct) (43, 44).
Primer Sequences
18S: Fw: 5′AACACGGGAAACCTCACCC3′;
Rv: 5′CCACCAACTAAGAACGGCCA3′; Tm: 60◦C
IL-6: Fw: 5′TGATGCACTTGCAGAAAACAA3′;
Rv: 5′GGTCTTGGTCCTTAGCCACTC3′; Tm: 60◦C
TNF-α: Fw: 5′CGGGCAGGTCTACTTTGGAG3′;
Rv: 5′ACCCTGAGCCATAATCCCCT3′; Tm: 62◦C
iNOS: Fw: 5′CACAGCAATATAGGCTCATCCA3′;
Rv: 5′GGATTTCAGCCTCATGGTAAAC3′; Tm: 60◦C
SOCS3: Fw: 5′CCTTTGACAAGCGGACTCTC3′;
Rv: 5′GCCAGCATAAAAACCCTTCA3′; Tm: 60◦C
IL-10: Fw: 5′CTCCCCTGTGAAAATAAGAGCA3′;
Rv: 5′TCCAGCAGACTCAATACACACT3′; Tm: 60◦C
IL-10R: Fw: 5′-TGTTTACTTATCACGACGGA3′;
Rv: 5′GACCAGGACTGTAGGCAACTT3′; Tm: 56◦C
Cytokine ELISA
IL-6, TNF-α, and IL-10 concentrations were measured in culture
supernatants using cytokine-specific OptEIATM ELISA kits
according to the manufacturer’s instructions (BD Biosciences,
USA). The reaction was detected using peroxidase-conjugated
Streptavidin, followed by incubation with hydrogen peroxide
as a substrate, and with ABTS (Sigma Aldrich Co., USA)
as a chromogen. Cytokine concentrations in samples were
interpolated from recombinant IL-6, TNF-α, and IL-10 standard
curves. Absorbance readings were made at 405 nm.
Protein Extraction and Western Blot
Analysis
Total protein extracts were prepared as described previously by
our group (6). Protein concentration was determined by the
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FIGURE 1 | The chemical structure of benznidazole (Bzl) used in this study is shown (A). Cardiomyocytes were treated with 15µM of Bzl for 30min and then with 10
mg/L LPS for 24 h. SOCS3 mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA (B). Results are expressed as the mean of three independent
experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS stimulated cells. Gray bar: LPS stimulated and Bzl treated
cells **P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells.
Bradford method using a commercial protein assay (Bio-Rad,
USA) and bovine serum albumin (BSA, Sigma-Aldrich Co, USA.)
as a standard (45).
Fifty microgram of protein extracts separated in 8–15% SDS-
PAGE gels were blotted onto a Hybond-P membrane (GE
Health-care, Spain) to detect SOCS3 (Elabscience R©, Cat# E-
AB-10603, USA), p-STAT3 (Tyr705) (BioLegend Antibody Cat#
690402, RRID:AB_2629819, USA), and α-actin (Santa Cruz
Biotechnology Cat# sc-1615, RRID:AB_630835, USA), using
specific antibodies, in a 1:500 dilution in PBS. Blots were
revealed by enhanced chemiluminescence in a BioSpectrum R©
Imaging Systems (UVP, Analytik Jena Company, USA). Band
intensity was analyzed using the NIH Image J software
(ImageJ, RRID:SCR_003070).
NO Measurement
To determine the amount of NO released into the culture
medium, nitrate was reduced to nitrite and measured
spectrophotometrically by the Griess reaction (46, 47). The
amount of NO in the culture supernatants was calculated by
interpolation of the samples absorbances at 540 nm using a
standard curve of NaNO2.
Immunofluorescence
Myocardial cells grown on round glass coverslips were fixed with
methanol and blocked with 3% BSA in PBS. The expression
of p-IKK and IκBα was determined by immunofluorescence,
as described previously (6). For this purpose, rabbit polyclonal
IgG anti- IκBα (Santa Cruz Biotechnology Cat# sc-1643,
RRID:AB_627772) or rabbit polyclonal IgG anti- p-IKK (Ser176)
(Santa Cruz Biotechnology Cat# sc-21661, RRID:AB_669364)
were used as primary antibodies at a 1:50 dilution, and Goat
anti-rabbit IgG Alexa Fluor 488 nm (Jackson ImmunoResearch
Labs Cat# 111-545-003, RRID:AB_2338046), or Goat anti-
Rabbit IgG Alexa Fluor 594 nm (Jackson ImmunoResearch Labs
Cat# 111-585-003, RRID:AB_2338059) were used at a 1:500
dilution as secondary antibodies. Cells nuclei were stained
with DAPI (300 nM). At least 30 random microscopic fields
(400X) and 1,000 cells per culture were acquired using a Spot
RT digital camera attached to an Eclipse 600 fluorescence
microscope (Nikon Inc., USA). Mean fluorescence intensity
(MFI) were quantified using Fiji Image J software (Fiji,
RRID:SCR_002285) (48).
Statistical Analysis
Data are expressed as themean of three independent experiments
± SEM (n = 3) for each experimental group (Five culture
replicates/group). One-way ANOVA was used to analyze the
statistical significance of the differences observed between
infected, treated or untreated groups. The Tukey post-hoc test
was performed to compare every mean with every other mean.
Differences were considered statistically significant when P <
0.05. All analyses were performed using the Prism 7.0 Software
(GraphPad Prism, RRID:SCR_002798).
RESULTS
LPS and Benznidazole Promote STAT3
Activation and SOCS3 Expression
In a previous work we found that T. cruzi and IL-10 promote
STAT3 phosphorylation and up-regulate the expression of
SOCS3 thereby preventing NF-κB nuclear translocation and
ERK1/2 phosphorylation (31). Besides, we determined that
the treatment with benznidazole 15µM was the optimal
concentration to clear parasite load in T. cruzi-infected primary
cultured cardiomyocytes, as measured by qPCR (6). These
findings led us to study its anti-inflammatory properties given
the optimal parasiticidal concentration found. We determined
that benznidazole 15µM reduced inflammatory mediators
via inhibition of the NF-κB pathway (6). In this work, we
sought to determine whether SOCS3 was involved in the anti-
inflammatory effects of benznidazole. To this aim, we set up
a model to dissociate the anti-parasitic effect of benznidazole
from its anti-inflammatory properties using LPS instead of live
parasites. Cultured cardiomyocytes were pre-treated with 15µM
benznidazole and stimulated with 10 mg/L of LPS. Interestingly,
an increase in SOCS3 mRNA level was observed 24 h after LPS
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FIGURE 2 | Cardiomyocytes were treated with 10µM Stattic, a specific inhibitor of STAT3, 30min before the addition of 15µM benznidazole (Bzl). Cells were
stimulated with 10 mg/L LPS 30min after Bzl treatment. After 15min, p-STAT expression was determined by Western blot with a specific antibody and normalized
against α-actin (A). After 24 h, SOCS3 mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA. After 48 h SOCS3 protein expression was
determined by Western blot with a specific antibody and normalized against α-actin (B). After 48 h, iNOS mRNA levels were analyzed by RT-qPCR and normalized
against 18S rRNA (C), and NO levels were quantified by the Griess reaction in culture supernatants (D). Results are expressed as the mean of three independent
experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS stimulated cells. Gray bar: LPS stimulated and Bzl treated
cells. Hatched gray bar: Stattic pre-treated, LPS stimulated and Bzl treated cells **P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells. øP < 0.05 vs.
Bzl-treated and LPS-stimulated cells.
stimulation. Moreover, pre-treatment with benznidazole further
increased SOCS3 expression significantly, as shown in Figure 1B.
Moreover, both LPS and benznidazole are able to induce
phosphorylation of STAT3. As expected, this effect was inhibited
by 10µMof Stattic, a STAT3 inhibitor (Figure 2A). Interestingly,
SOCS3 increase was precluded by Stattic, suggesting that
benznidazole increased SOCS3 mRNA expression in a STAT3-
dependent manner (Figure 2B). As expected, Western blot
showed an increase in SOCS3 protein expression after LPS
stimulation and even more in LPS-stimulated and benznidazole-
treated cardiomyocytes. Furthermore, lower SOCS3 expression
upon treatment with Stattic of LPS-stimulated and benznidazole-
treated cardiomyocytes was observed (Figure 2B).
Earlier, we reported that while LPS increases the expression
of iNOS and the release of NO by cardiomyocytes,
benznidazole inhibits these responses (6). In this work we
assessed the participation of STAT3 in the inhibitory effect
of benznidazole on these inflammatory mediators. When
STAT3 is inhibited, benznidazole neither prevents iNOS
expression (Figure 2C) nor NO release (Figure 2D), pointing
out that STAT3 is involved in the anti-inflammatory
effect of benznidazole.
SOCS3 Is Involved in the Anti-inflammatory
Effects Exerted by Benznidazole
In order to determine whether SOCS3 participates in the
inhibition of inflammatory mediators, we accomplished specific
knockdown of SOCS3 with siRNA in cultured cardiomyocytes.
Then, cells were pre-treated with benznidazole and stimulated
with LPS. IL-6 and TNF-α expression and their concentrations
in culture supernatants were evaluated. Figure 3A shows that
benznidazole inhibited IL-6 and TNF-α mRNA expression.
Conversely, when SOCS3 was silenced, benznidazole was unable
to modulate the expression of these pro-inflammatory cytokines.
In agreement with this benznidazole could not inhibit the
release of IL-6 and TNF-α to culture supernatants upon
SOCS3 silencing (Figure 3B). Also, under silencing conditions of
SOCS3, benznidazole neither inhibited iNOS mRNA expression
nor NO production in LPS-stimulated cells (Figure 3C).
Benznidazole Inhibits IKK/NF-κB Activation
Through SOCS3
The transcription factor NF-κB is known to participate in the
induction of pro-inflammatory genes. We previously showed
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FIGURE 3 | Cardiomyocytes were transfected with SOCS3 siRNA. After 72 h, cells were treated with 15µM benznidazole (Bzl) for 30min and then with 10 mg/L LPS.
After 4 h, IL-6 and TNF-α mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA (A). Concentration of cytokines in culture supernatants was
measured by ELISA (B). After 48 h, iNOS mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA and NO levels were quantified by the Griess
reaction in culture supernatants (C). Results are expressed as the mean of three independent experiments (n = 3, 5 replicates/treatment) ± SEM. White bar:
Unstimulated control cells. Black bar: LPS stimulated cells. Gray bar: LPS-stimulated and Bzl-treated cells. Hatched gray bar: SOCS3 silenced, LPS-stimulated and
Bzl-treated cells. **P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells. øP < 0.05 vs. Bzl-treated and LPS-stimulated cells.
that a low dose of benznidazole reduces the expression of
inflammatory mediators by inhibiting NF-κB pathway, although
the mechanism involved is poorly understood (6). Therefore, in
this work we designed a set of experiments to evaluate whether
SOCS3 participates in the effects of benznidazole on the NF-
κB pathway. Figure 4A shows IKK phosphorylation visualized
using a fluorescence microscopy upon challenge for 15min with
LPS. When benznidazole was added, IKK phosphorylation was
inhibited. However, when SOCS3 was silenced, benznidazole
could not inhibit IKK phosphorylation. Similar results were
obtained when we evaluated cytosolic IκBα degradation. The
NF-κB inhibitor, IκBα, underwent degradation upon stimulation
with LPS and this effect was prevented in the presence of
benznidazole. The participation of SOCS3 was confirmed, since
benznidazole did not inhibit the degradation of IκBα promoted
by LPS stimulation in the cells in which SOCS3 was silenced
(Figure 4B).
IL-10 Participates in Benznidazole
Anti-inflammatory Effects
IL-10 is a key inhibitor of many aspects of the inflammatory
response. In previous reports, we highlighted the relevance of
IL-10 in the modulation of the pro-inflammatory response of
cardiomyocytes in Chagas disease. We showed that recombinant
mouse IL-10 acts as a negative regulator of pro-inflammatory
signaling by up-regulation of SOCS3 in cardiomyocytes infected
with T. cruzi (31). Moreover, it has been reported that
peripheral blood mononuclear cells isolated from patients in
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FIGURE 4 | Cardiomyocytes were transfected with SOCS3 siRNA. After 72 h, cells were treated with 15µM of benznidazole (Bzl) for 30min and then with 10 mg/L
LPS. p-IKK (15min) (A), and IκBα (30min) (B) expression was detected by immunofluorescence with a rabbit polyclonal IgG anti- p-IKK or anti- IκBα (primary
antibodies), and Goat anti-rabbit IgG Alexa Fluor 488 or Alexa Fluor 594 (secondary antibodies), respectively. Cell nuclei were stained with 300 nM DAPI.
Representative microphotographs (400x) are shown. Mean fluorescence intensity (MFI) was quantified using Fiji Software, and the results are expressed as the mean
of three independent experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS-stimulated cells. Gray bar:
LPS-stimulated and Bzl-treated cells. Hatched gray bar: SOCS3- silenced, LPS-stimulated and Bzl-treated cells. **P < 0.001, vs. LPS-stimulated cells; ##P < 0.001
vs. control cells. øP < 0.05 vs. Bzl-treated and LPS-stimulated cells.
FIGURE 5 | Cardiomyocytes were treated with 15µM of benznidazole (Bzl) for 30min and then with 10 mg/L LPS. After 24 h, IL-10 and IL-10 receptor (IL-10R)
mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA. Concentration of IL-10 in culture supernatants was measured by ELISA. Results are
expressed as the mean of three independent experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS-stimulated
cells. Gray bar: LPS-stimulated and Bzl-treated cells.
the indeterminate phase of Chagas disease produce higher
levels of IL-10 than those isolated from patients with chronic
cardiomyopathy (49, 50).
In order to establish whether IL-10 could be involved in
the effects of benznidazole, we evaluated the expression of IL-
10 and its receptor in LPS-stimulated and benznidazole pre-
treated cardiomyocytes as well as the release of IL-10 to culture
supernatants. Figure 5 shows a trend to increase the expression of
IL-10 and its release to culture medium, as well as the expression
of IL-10R in cardiomyocytes stimulated with LPS, and that pre-
treatment with benznidazole further increases this trend.
Moreover, to determine whether benznidazole requires IL-
10 for the increase of SOCS3, we evaluated the expression of
SOCS3 in neonatal cardiomyocytes isolated from IL-10-knockout
mice (41). Figure 6 shows that LPS increases SOCS3 mRNA
expression in IL-10-knockout cardiomyocytes. However, when
these cells were pre-incubated with benznidazole, its expression
did not increase, strongly suggesting that benznidazole induction
of SOCS3 depends on IL-10 signaling.
In the same direction we observed that benznidazole fails
to modulate the expression of IL-6, TNF-α, and iNOS in
cardiomyocytes lacking IL-10 (Figure 7). In addition, when
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FIGURE 6 | Cardiomyocytes from BALB/c and IL-10-knockout (IL-10-KO)
mice of BALB/c background were treated with 15µM of benznidazole (Bzl) for
30min and then with 10 mg/L LPS for 24 h. SOCS3 mRNA levels were
analyzed by RT-qPCR and normalized against 18S rRNA. Results are
expressed as the mean of three independent experiments (n = 3, 5
replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar:
LPS-stimulated cells. Gray bar: LPS-stimulated and Bzl-treated cells.
**P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells.
we evaluated NO release to culture supernatant, the secretion
induced by LPS cannot be inhibited by benznidazole in IL-10
knockout cardiomyocytes (Figure 8A), and this was restored in
the presence of recombinant IL-10 (Figure 8B).
Furthermore, benznidazole could not avoid the
phosphorylation of IKK (Figure 9A) and degradation of
IκBα (Figure 9B) in IL-10-knockout mice, as shown by
immunofluorescence microscopy. This confirms that IL-10 is
required for the benznidazole-mediated inhibition of NF-κB.
DISCUSSION
Benznidazole is one of the anti-parasitic drugs currently used
in the treatment of Chagas disease. This drug has also anti-
inflammatory effects, the mechanisms of which have not been
fully elucidated yet. During the acute infection, the inflammatory
response must be critically balanced. Although necessary for the
control of parasite proliferation, inflammation results in tissue
damage, leading to progressive myocardial fibrosis, and cardiac
remodeling, ultimately leading to heart failure. The evolution of
this disease causes major disabilities with high economic and
social impact (51). For these reasons, besides controlling the
parasite load, control of the inflammatory response both in the
early and chronic stages of the infection is especially important.
Although benznidazole is one of the main drugs used in
the treatment of acute and early chronic Chagas disease, there
are serious limitations, such as the side effects exhibited by a
significant proportion of patients (52). These include organic
manifestations indicative of systemic toxicity. Adverse effects
symptoms are evident in the first days of treatment and
represent a major threat of benznidazole in clinical use with
frequent therapy discontinuation (52–56). In a previous work we
described, for the first time, that benznidazole has parasiticidal
properties, in vivo as well as in vitro, at doses or concentrations
lower than those previously reported for a highly virulent T. cruzi
strain. In addition, treatment with a low dose of benznidazole
was also able to inhibit the expression of inflammatory mediators
and tissue inflammation in an experimental model of Chagas
disease (6). In vitro studies using primary culture cardiomyocytes
infected with the virulent RA strain of T. cruzi showed that
15µM benznidazole was the optimal concentration to reduce
the parasite load as well as the inflammatory mediators in the
infected cells (6). This finding led us to search for the mechanism
of action involved in the anti-inflammatory effects, knowing
the optimal parasiticidal concentration and considering that
this is the only antiparasitic treatment currently available in
many countries.
In a previous work, we found that T. cruzi and IL-10 promotes
STAT3 phosphorylation and up-regulates the expression of
SOCS3 thereby preventing NF-κB nuclear translocation and
ERK1/2 phosphorylation, two of the pathways known to promote
the expression of pro-inflammatory genes (31).
In this work we focused on the pathways through which
benznidazole exerts anti-inflammatory effects, demonstrating
the IL-10/STAT3/SOCS3 axis is involved. To this aim we
proceeded to dissociate the antiparasitic effects and anti-
inflammatory properties of benznidazole using an in vitromodel
of primary culture cardiomyocytes pre-treated with benznidazole
and stimulated with LPS. We report, for the first time, that
benznidazole increases SOCS3 expression.
It has been described that phosphorylated STAT3 is dimerized
and induces transcription of the SOCS3 gene (57). Also, it
has been reported that the induction of SOCS3 expression in
macrophages infected with Mycobacterium tuberculosis leads to
the inhibition of NF-κB activation as a mechanism of immune
evasion (58). Moreover, Carow et al. demonstrated that SOCS3,
both in myeloid and T cells, is essential for resistance against M.
tuberculosis via discrete mechanisms (59).
In the 1960s, it was postulated that the production of reactive
oxygen species (ROS) would be one of the mechanisms capable of
killing pathogens during the respiratory outbreak by phagocytes
(60). In the same way, the trypanocidal activity of benznidazole,
for instance, was credited to its capability to cause oxidative
damage to the parasite (61). Paradoxically, it is also suggested
that oxidative environments would stimulate parasite growth
(62). However, it must be borne in mind that excessive ROS
production and secretion to the tissue milieu can be detrimental
to the host in the context of persistent inflammation.
Taking into consideration that T. cruzi can activate STAT3,
and also increase SOCS3 expression (31), we wondered whether
benznidazole was also able to promote STAT3 activation. In the
current work we show that LPS also increases SOCS3. Moreover,
the addition of benznidazole increases SOCS3 more than 50-
fold with respect to LPS. Interestingly, both IL-10 and IL-6
induce the activation of STAT3, yet generate different cellular
responses. While IL-6 stimulation promotes a pro-inflammatory
response, IL-10 signaling induces a strong anti-inflammatory one
(36). The increase in SOCS3 in LPS-stimulated cardiomyocytes
might be dependent on the IL-6 pathway of STAT3 activation,
since we observed a significant amount of IL-6 in the cell
supernatants at 48 h. We hypothesized that up-regulation of
SOCS3 in benznidazole-treated cardiomyocytes was mediated
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FIGURE 7 | Cardiomyocytes from BALB/c and IL-10-knockout (IL-10-KO) mice of BALB/c background were treated with 15µM of benznidazole (Bzl) for 30min and
then with 10mg/L LPS. After 4 h, IL-6 (A) and TNF-α (B) mRNA levels were analyzed by RT-qPCR and normalized against 18S rRNA. After 48 h, iNOS mRNA levels
were analyzed by RT-qPCR and normalized against 18S rRNA (C). Results are expressed as the mean of three independent experiments (n = 3, 5
replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS-stimulated cells. Gray bar: LPS-stimulated and Bzl-treated cells. **P < 0.001, vs.
LPS-stimulated cells; ##P < 0.001 vs. control cells.
FIGURE 8 | Cardiomyocytes from BALB/c and IL-10-knockout (IL-10-KO) mice of BALB/c background were treated with 15µM of benznidazole (Bzl) for 30min and
then with 10mg/L LPS. After 48 h NO levels were quantified by the Griess reaction in culture supernatants (A). Cardiomyocytes from IL-10-KO mice were treated with
50 ng/ml of recombinant mouse IL-10 (rIL-10) for 30min before Bzl treatment and LPS stimulation. After 48 h NO levels were quantified by the Griess reaction in
culture supernatants (B). Results are expressed as the mean of three independent experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated
control cells. Black bar: LPS-stimulated cells. Gray bar: LPS-stimulated and Bzl treated cells. Light-Gray bar: rIL-10- and Bzl-treated, LPS stimulated cells.
**P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells. øP < 0.05 vs. Bzl treated-LPS-stimulated cells.
through IL-10. This was confirmed in our model using IL-
10KO cardiomyocytes, in which upregulation of SOCS3 is not
observed. Furthermore, the increase of SOCS3 was precluded by
Stattic, suggesting that benznidazole increases SOCS3 expression
in a STAT3-dependent manner. Previously, we reported that
benznidazole inhibits iNOS and consequently NO release in LPS
stimulated cardiomyocytes (6). In this work, we demonstrate the
participation of STAT3 in the inhibitory effect of benznidazole
since when STAT3 was inhibited by Stattic, benznidazole could
neither inhibit the expression of iNOS nor the release of NO.
Furthermore, when SOCS3 was silenced in cardiomyocytes
stimulated with LPS, using SOCS3-specific siRNA, benznidazole
neither inhibited the expression nor the release of inflammatory
cytokines. Similar effects were observed for the expression of
iNOS and release of NO to the culture medium.
It has been described that SOCS3 exerts its anti-inflammatory
effects by inhibition of the activation of the NF-κB pathway
(63). In this regard, it has been demonstrated that the PPE18
protein of M. tuberculosis up-regulates the expression as well
as tyrosine phosphorylation of SOCS3. Phosphorylated SOCS3
physically interacts with the IκBα-NFκB/rel complex, inhibiting
phosphorylation of IκBα and thus inactivates the NF-κB pathway
(58).Moreover, we have demonstrated that knockdown of SOCS3
by specific siRNA, impedes the IL-10-mediated inhibition of
NFκB and ERK1/2 activation in cardiomyocytes infected with T.
cruzi (31). Furthermore, we previously showed that a low dose of
benznidazole reduces the expression of inflammatory mediators
by inhibiting the NFκB pathway (6). In this work we demonstrate
the participation of SOCS3 in the effects of benznidazole, because
when this cytokine suppressor was silenced in cardiomyocytes
stimulated with LPS, the treatment with benznidazole could
neither inhibit the IKK phosphorylation nor prevent IκBα
degradation. Therefore, under conditions that preclude SOCS3
signaling, the NF-κB pathway cannot be inhibited.
Previously, we have demonstrated that the treatment with
mouse recombinant IL-10, acts as a negative regulator of
pro-inflammatory signaling by up-regulation of SOCS3 in
cardiomyocytes infected with T. cruzi (31). Then, we sought to
determine whether IL-10 was involved in the anti-inflammatory
effects mediated by benznidazole. Our results showed, first of all,
that LPS and LPS plus benznidazole increase the release of IL-
10 and the expression of its receptor. Interestingly, the assays
show that the increase in the expression of SOCS3 depends on
the presence of IL0, since benznidazole was unable to increase
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FIGURE 9 | Cardiomyocytes from BALB/c and IL-10-knockout (IL-10-KO) mice of BALB/c background were treated with 15µM of benznidazole (Bzl) for 30min and
then with 10 mg/L LPS. p-IKK (15min) (A) and IκBα (30min) (B) expression was detected by immunofluorescence with a rabbit polyclonal IgG anti- p-IKK or anti- IκBα
(primary antibodies), and Goat anti-rabbit IgG Alexa Fluor 488 or Alexa Fluor 594 (secondary antibodies), respectively. Cell nuclei were stained with 300 nM DAPI.
Representative microphotographs (400x) are shown. Mean fluorescence intensity (MFI) was quantified using Fiji Software, and the results are expressed as the mean
of three independent experiments (n = 3, 5 replicates/treatment) ± SEM. White bar: Unstimulated control cells. Black bar: LPS-stimulated cells. Gray bar:
LPS-stimulated and Bzl-treated cells. **P < 0.001, vs. LPS-stimulated cells; ##P < 0.001 vs. control cells.
the expression of SOCS3 in cardiomyocytes from IL-10-knockout
mice. Secondly, benznidazole failed to inhibit the expression
of inflammatory mediators in IL-10-knockout cells. There are
evidences about the participation of SOCS3 in the mechanism
by which IL-10 modulates the inflammatory response. In this
regard, it has been reported that SOCS3 is the key mediator of the
inhibitory effects of IL-10 in macrophages stimulated with LPS
(64–66), and in an in vivo model of collagen induced arthritis
(67). Moreover, our previous results highlight the relevance
of IL-10 in the modulation of pro-inflammatory response in
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FIGURE 10 | Parasiticidal concentrations of benznidazole (Bzl) exert anti-inflammatory effects through IL-10/STAT3/SOCS3 axis. When cardiomyocytes are
stimulated with LPS and pre-treated with 15µM of Bzl, IL-10 expression tends to increase. This induces the phosphorylation of STAT3 resulting in an increase in
SOCS3 expression, thereby preventing NF-κB activation.
cardiomyocytes infected with T. cruzi, as we demonstrated that
the IL-10/STAT3/SOCS3 axis negatively regulates NF-κB and
ERK/MAPK–dependent gene expression of pro-inflammatory
mediators (31). Furthermore, the relevance of IL-10 was evident
as we demonstrated that benznidazole can neither inhibit IKK
phosphorylation nor prevent the degradation of IκBα in cardiac
cells from IL-10-knockout mice. Thus, IL-10 is required for
the inhibitory effects of benznidazole on the NF-κB pathway
to take place. Lastly, it has been widely described that the
modulatory effects of IL-10 on the inflammatory response are
associated with the inhibition of the NF-κB pathway (68–
70), making IL-10 a reasonable mediator of benznidazole anti-
inflammatory mechanisms.
In summary, we show for the first time, that the IL-
10/STAT3/SOCS3 axis is involved in the anti-inflammatory
effects of benznidazole (Figure 10). These findings may
add up to new therapeutic strategies for the treatment of
chronic Chagas disease given both its anti-parasitic and
inflammatory properties.
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